Latest Car T News

AdAlta Limited and its subsidiary AdCella have partnered with Shanghai Cell Therapy Group to co-develop a pioneering CAR-T cancer therapy targeting solid tumours outside China. This collaboration aims to bring a novel, armored immunotherapy with promising clinical results to global markets.

Arovella Therapeutics has taken a significant step forward by submitting an IND application to the U.S. FDA for its lead CAR-iNKT cell therapy, ALA-101, targeting blood cancers. This milestone paves the way for a first-in-human Phase 1 trial in both Australia and the U.S.

Jayride Group Limited reports a reduced quarterly loss and secures fresh capital, yet faces ongoing uncertainty over its ability to continue as a going concern during its ASX reinstatement process.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

INOVIQ Limited has reported compelling preclinical results for its CAR-NK-exosome therapy targeting triple-negative breast cancer, showing significant tumor reduction and perfect survival in treated mice.

Harmoney Corp Limited reported a staggering 742% increase in Cash NPAT for FY25, driven by its new Stellare® 2.0 platform and operational efficiencies. The company reaffirmed its ambitious $12 million profit target for FY26 while unveiling a secured car loan product and securing a major bank debt facility.

Imugene Limited has received positive feedback from the FDA, aligning key requirements to progress its azer-cel therapy into a pivotal clinical trial, underscoring its growing promise in blood cancer treatment.

Imugene has secured FDA backing to advance its allogeneic CAR T therapy, azer-cel, into a pivotal Phase 3 trial targeting difficult-to-treat diffuse large B-cell lymphoma (DLBCL), including patients relapsed after prior CAR-T treatment.

Chimeric Therapeutics has won FDA Orphan Drug Designation for its CHM CDH17 CAR-T therapy targeting gastric cancer, advancing its clinical development with regulatory incentives and potential market exclusivity.

Imugene Limited and JW Therapeutics have launched a strategic collaboration to combine oncolytic virus and CAR-T cell therapies, aiming to tackle refractory solid tumors through a pioneering 'mark and kill' approach.

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.

Autosports Group Limited reports record FY25 revenue and profit, while announcing a strategic acquisition of 10 Barry Bourke Motors dealerships in Victoria, signaling robust growth momentum into FY26.